Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $8
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a Buy rating on Bioventus (NASDAQ:BVS) and raises the price target from $7 to $8.
May 08, 2024 | 4:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst William Plovanic maintains a Buy rating on Bioventus and raises the price target from $7 to $8.
The upgrade in price target by a reputable analyst like William Plovanic signals a positive outlook on Bioventus, likely leading to increased investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100